HSR23-101: Characteristics and Outcomes of Patients Treated With Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases

Authors:
Naleen Raj BhandariEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN

Search for other papers by Naleen Raj Bhandari in
Current site
Google Scholar
PubMedClose
 BPharm, MS, PhD
,
Neha BansalEli Lilly Services India Private Limited, Bengaluru, India

Search for other papers by Neha Bansal in
Current site
Google Scholar
PubMedClose
 MA
,
Chi-Wei DuannEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN

Search for other papers by Chi-Wei Duann in
Current site
Google Scholar
PubMedClose
 MD
,
Anasofia AfonsoEli Lilly Nederland BV, Papendorpseweg, Utrecht, The Netherlands

Search for other papers by Anasofia Afonso in
Current site
Google Scholar
PubMedClose
 PhD
, and
Shen ZhengTechData Service Company, King of Prussia, PA

Search for other papers by Shen Zheng in
Current site
Google Scholar
PubMedClose
 PhD
View More View Less
Volume/Issue:
Volume 21: Issue 3.5
Online Publication Date:
31 Mar 2023
DOI:
https://doi.org/10.6004/jnccn.2022.7172
Restricted access

Corresponding Author: Naleen Raj Bhandari, BPharm, MS, PhD

Email: nrbhandari@lilly.com
  • Collapse
  • Expand
Copyright:
Copyright © 2023 by the National Comprehensive Cancer Network 2023
Article Category:
Abstract
Print Publication Date:
31 Mar 2023
Online Publication Date:
31 Mar 2023
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 81 81 11
PDF Downloads 0 0 0
EPUB Downloads 0 0 0